CN106132941B - 用于治疗皮肤病的苯并恶嗪酮衍生物 - Google Patents

用于治疗皮肤病的苯并恶嗪酮衍生物 Download PDF

Info

Publication number
CN106132941B
CN106132941B CN201580005383.4A CN201580005383A CN106132941B CN 106132941 B CN106132941 B CN 106132941B CN 201580005383 A CN201580005383 A CN 201580005383A CN 106132941 B CN106132941 B CN 106132941B
Authority
CN
China
Prior art keywords
skin
disease
compound
klk7
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580005383.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN106132941A (zh
Inventor
F·沃格贝里
G·莱昂纳德松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xikesi Pull Pharmaceutical Co
Original Assignee
Xikesi Pull Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xikesi Pull Pharmaceutical Co filed Critical Xikesi Pull Pharmaceutical Co
Publication of CN106132941A publication Critical patent/CN106132941A/zh
Application granted granted Critical
Publication of CN106132941B publication Critical patent/CN106132941B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/539—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more oxygen atoms in the same ring, e.g. dioxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
    • C07D265/22—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201580005383.4A 2014-01-23 2015-01-22 用于治疗皮肤病的苯并恶嗪酮衍生物 Active CN106132941B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1430003-2 2014-01-23
SE1430003 2014-01-23
PCT/SE2015/050062 WO2015112081A1 (en) 2014-01-23 2015-01-22 Benzoxazinone derivatives for treatment of skin diseases

Publications (2)

Publication Number Publication Date
CN106132941A CN106132941A (zh) 2016-11-16
CN106132941B true CN106132941B (zh) 2018-04-06

Family

ID=53681747

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580005383.4A Active CN106132941B (zh) 2014-01-23 2015-01-22 用于治疗皮肤病的苯并恶嗪酮衍生物

Country Status (18)

Country Link
US (2) US9695194B2 (enExample)
EP (1) EP3097085B1 (enExample)
JP (1) JP6448651B2 (enExample)
CN (1) CN106132941B (enExample)
AU (1) AU2015209761B2 (enExample)
CA (1) CA2934025C (enExample)
CY (1) CY1123477T1 (enExample)
DK (1) DK3097085T3 (enExample)
ES (1) ES2820868T3 (enExample)
HR (1) HRP20201500T1 (enExample)
HU (1) HUE051296T2 (enExample)
LT (1) LT3097085T (enExample)
PL (1) PL3097085T3 (enExample)
PT (1) PT3097085T (enExample)
RS (1) RS60830B1 (enExample)
SI (1) SI3097085T1 (enExample)
SM (1) SMT202000557T1 (enExample)
WO (1) WO2015112081A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015112081A1 (en) * 2014-01-23 2015-07-30 Sixera Pharma Ab Benzoxazinone derivatives for treatment of skin diseases
ES2923515T3 (es) * 2015-05-13 2022-09-28 Nihon Nohyaku Co Ltd Compuesto de éster de ácido antranílico, microbicida agrícola y hortícola que comprende el compuesto, y método para utilizar el microbicida
EP4059570A1 (en) * 2016-01-13 2022-09-21 Children's Hospital Medical Center Compositions and methods for treating allergic inflammatory conditions
JP2020527357A (ja) * 2017-06-16 2020-09-10 アジトラ インコーポレーテッド Ｌｅｋｔｉ発現組換え微生物を用いたネザートン症候群の処置のための組成物および方法
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
WO2019204580A1 (en) 2018-04-20 2019-10-24 Children's Hospital Medical Center Blood biomarker for eosinophilic gastrointestinal disorders
GB201809378D0 (en) 2018-06-07 2018-07-25 Glaxosmithkline Ip Dev Ltd Novel compounds
US12297501B2 (en) 2019-02-25 2025-05-13 Children's Hospital Medical Center Methods for diagnosing and treating eosinophilic gastritis
CN114423791B (zh) 2019-09-18 2026-01-09 豪夫迈·罗氏有限公司 抗klk7抗体、抗klk5抗体、多特异性抗klk5/klk7抗体及使用方法
EP4037687B1 (en) 2019-10-01 2025-10-29 Molecular Skin Therapeutics, Inc. Benzoxazinone compounds as klk5/7 dual inhibitors
GB202001447D0 (en) * 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
BR102020009679A2 (pt) 2020-05-14 2021-11-23 Fundação Universidade Federal Do Abc - Ufabc Anticorpos recombinantes humanos para inibição da calicreína tecidual humana 7 (klk7) e uso em doenças relacionadas ao processo de descamação da pele
TW202304890A (zh) * 2021-04-14 2023-02-01 美商百歐克斯製藥公司 Klk5雙環雜芳香族抑制劑
JP2024520154A (ja) * 2021-06-01 2024-05-21 シクセラ・ファーマ・アーベー ６－エトキシ－７－メトキシ－２－（２－メチルスルファニルフェニル）－３，１－ベンゾオキサジン－４－オンの水中油型乳剤

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB115399A (en) * 1917-03-28 1918-04-29 Reginald Guley Lewis Improved Delivery mechanism for Coin-freed Apparatus and the like.
WO1999048878A1 (en) * 1998-03-24 1999-09-30 Novo Nordisk A/S Heterocyclic compounds regulating clotting
CN101152185A (zh) * 2003-06-06 2008-04-02 阿里克斯股份公司 杂环化合物作为scce抑制剂的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1153994A (en) 1965-07-21 1969-06-04 Aspro Nicholas Ltd Hydroxyphenyl Anthranilic Acid Derivatives Capable of Absorbing 'Ultra-Violet Light and Compositions containing them
TWI419884B (zh) * 2010-06-24 2013-12-21 Univ Chang Gung 苯并雜氧嗪酮衍生物，其製備方法以及包含有此等衍生物的藥學組成物
WO2015112081A1 (en) * 2014-01-23 2015-07-30 Sixera Pharma Ab Benzoxazinone derivatives for treatment of skin diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB115399A (en) * 1917-03-28 1918-04-29 Reginald Guley Lewis Improved Delivery mechanism for Coin-freed Apparatus and the like.
WO1999048878A1 (en) * 1998-03-24 1999-09-30 Novo Nordisk A/S Heterocyclic compounds regulating clotting
CN101152185A (zh) * 2003-06-06 2008-04-02 阿里克斯股份公司 杂环化合物作为scce抑制剂的用途

Also Published As

Publication number Publication date
AU2015209761B2 (en) 2018-11-29
HUE051296T2 (hu) 2021-03-01
LT3097085T (lt) 2020-10-12
SI3097085T1 (sl) 2020-11-30
US20170002021A1 (en) 2017-01-05
RS60830B1 (sr) 2020-10-30
JP6448651B2 (ja) 2019-01-09
CY1123477T1 (el) 2022-03-24
WO2015112081A1 (en) 2015-07-30
AU2015209761A1 (en) 2016-07-07
SMT202000557T1 (it) 2020-11-10
ES2820868T3 (es) 2021-04-22
CN106132941A (zh) 2016-11-16
PL3097085T3 (pl) 2021-01-11
JP2017503798A (ja) 2017-02-02
US9695194B2 (en) 2017-07-04
US20170267692A1 (en) 2017-09-21
EP3097085A1 (en) 2016-11-30
CA2934025A1 (en) 2015-07-30
HRP20201500T1 (hr) 2020-12-25
DK3097085T3 (da) 2020-10-26
US10072024B2 (en) 2018-09-11
EP3097085A4 (en) 2017-08-09
CA2934025C (en) 2022-06-07
EP3097085B1 (en) 2020-07-29
PT3097085T (pt) 2020-10-08

Similar Documents

Publication Publication Date Title
CN106132941B (zh) 用于治疗皮肤病的苯并恶嗪酮衍生物
JP7000394B2 (ja) 補因子の非存在下で凝固活性を有する、及び／又は、第ｉｘ因子凝固活性が増加した第ｉｘ因子変異体、並びに、出血性疾患を処置するためのその使用
Mittal et al. Intricate functions of matrix metalloproteinases in physiological and pathological conditions
Johnson et al. Matrix metalloproteinases
Podgorski et al. Cathepsin B and its role (s) in cancer progression
Ruddy et al. Multidimensional contribution of matrix metalloproteinases to atherosclerotic plaque vulnerability: multiple mechanisms of inhibition to promote stability
JP6932386B2 (ja) 新しいカリクレイン７阻害剤
Qi et al. Blockade of asparagine endopeptidase inhibits cancer metastasis
JP2022513919A (ja) 血栓性または血小板塞栓性疾患および／または血栓性または血小板塞栓性合併症の治療および／または予防のための置換オキソピリジン誘導体
Chakraborti et al. Implications of calpains in health and diseases
JP2017505299A5 (enExample)
HK1229792A1 (en) Benzoxazinone derivatives for treatment of skin diseases
HK1229792B (en) Benzoxazinone derivatives for treatment of skin diseases
Irtegün Kandemir et al. Altered expression of ADAMTSs and HAPLNs in preeclamptic placenta
Das et al. Insights into the Role of Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Health and Disease
HK40107125A (zh) 活性抑制和/或产生抑制剂
HK1229791B (zh) 新的激肽释放酶7抑制剂
Wells et al. Calpain
HK1229791A1 (en) New kallikrein 7 inhibitors
Fanjul Fernández New animal models and next-generation sequencing approaches for the functional analysis of cancer progression

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1229792

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant